Protagonist Therapeutics, Inc. (PTGX): Price and Financial Metrics


Protagonist Therapeutics, Inc. (PTGX)

Today's Latest Price: $19.97 USD

0.54 (2.78%)

Updated Sep 25 4:00pm

Add PTGX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

PTGX Stock Summary

  • Of note is the ratio of Protagonist Therapeutics Inc's sales and general administrative expense to its total operating expenses; only 9.35% of US stocks have a lower such ratio.
  • PTGX's price/sales ratio is 43.95; that's higher than the P/S ratio of 95.46% of US stocks.
  • Revenue growth over the past 12 months for Protagonist Therapeutics Inc comes in at 808.42%, a number that bests 99.01% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Protagonist Therapeutics Inc, a group of peers worth examining would be MORF, MGNX, VBLT, XENE, and CRBP.
  • PTGX's SEC filings can be seen here. And to visit Protagonist Therapeutics Inc's official web site, go to www.protagonist-inc.com.
PTGX Daily Price Range
PTGX 52-Week Price Range

PTGX Stock Price Chart Technical Analysis Charts


PTGX Price/Volume Stats

Current price $19.97 52-week high $23.25
Prev. close $19.43 52-week low $4.47
Day low $19.04 Volume 217,786
Day high $20.18 Avg. volume 532,085
50-day MA $19.06 Dividend yield N/A
200-day MA $12.49 Market Cap 735.04M

Protagonist Therapeutics, Inc. (PTGX) Company Bio


Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded in 2006 and is based in Milpitas, California.


PTGX Latest News Stream


Event/Time News Detail
Loading, please wait...

PTGX Latest Social Stream


Loading social stream, please wait...

View Full PTGX Social Stream

Latest PTGX News From Around the Web

Below are the latest news stories about Protagonist Therapeutics Inc that investors may wish to consider to help them evaluate PTGX as an investment opportunity.

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

Protagonist Therapeutics Reports Granting of Inducement Award

NEWARK, Calif., Sept. 15, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on September 15, 2020, it issued an inducement award to Matthew Gosling, the Company's recently hired Executive Vice President and General Counsel, in accordance with the terms…

PR Newswire | September 15, 2020

The Daily Biotech Pulse: Positive Readout From Galapagos, Intersect ENT Strikes Distribution Deal, Sol Gel's Regulatory Filing Accepted For Review

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 10) Agenus Inc (NASDAQ: AGEN ) Akouos Inc (NASDAQ: AKUS ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silk Road Medical Inc (NASDAQ: SILK ) Shockwave Medical Inc (NASDAQ: SWAV ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 10) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC )(reac...

Benzinga | September 11, 2020

Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference

NEWARK, Calif. , Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual H.C. Wainwright 22nd Annual Global Investment Conference. … Full story available on Benzinga.com

Benzinga | September 10, 2020

The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Fluidigm Corporation (NASDAQ: FLDM ) ( announced emergency use authorization for its saliva-based COVID-19 test) Generation Bio Co (NASDAQ: GBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Ocular Therapeutix Inc (NASDAQ: OCUL ) PPD Inc (NASDAQ: PPD ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Revance Therapeutics Inc (NASDAQ: RVNC ) Silk Road Medical Inc (NASDAQ: SILK ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Polypid Ltd (NASDAQ: PYPD ) Stocks In Focus FDA Approves Companion Diagnos...

Benzinga | August 27, 2020

Read More 'PTGX' Stories Here

PTGX Price Returns

1-mo -10.45%
3-mo 14.84%
6-mo 182.86%
1-year 51.86%
3-year 11.07%
5-year N/A
YTD 183.26%
2019 4.75%
2018 -67.64%
2017 -5.41%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7749 seconds.